Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
05/17/2012
Trade Name:
Pertzye
Generic Name or Proper Name (*):
pancrelipase
Indications Studied:
Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions
Label Changes Summary:
Safety and efficacy assessed in a clinical trial that included 10 patients 8 - 17 years Safety and efficacy of pancreatic enzyme products with different formulations of the same active ingredient for use in children have been described in medical literature and through clinical experience Use in children is limited by the available capsule dosage strengths and their ability to provide the recommended dose based on age and weight. Attempting to divide the capsule contents in small fractions to deliver small doses of lipase is not recommended High doses of pancreatic enzyme products have been associated with fibrosing colonopathy in children <12 years of age Capsule should be swallowed whole. Capsule and contents should not be crushed or chewed For patients unable to swallow intact capsules, the contents may be sprinkled on soft acidic food such as applesauce and swallowed immediately Not interchangeable with other pancrelipase products New drug
Product Labeling:
Labeling
PREA(P):
P
NNPS:
FALSE'
Therapeutic Category:
Pancreatic enzyme
-
-